OzUK Proud to be part of team to tackle trigeminal neuralgia

Oxford Cannabinoid Technologies has signed new partnership agreement with OzUK to target the chronic pain condition trigeminal neuralgia (TN), which causes severe facial pain caused by compression of the trigeminal nerve. Oz-UK Ltd, will facilitate the development of a cannabinoid metered-dose inhaler formulation, which will include studies aiming to identify and define the excipient/formulation components, as well as the selection of the canister, valve, and actuator. Learn more about our partnership here